AssetMark Inc
XERS icon

AssetMark Inc’s Xeris Biopharma Holdings XERS Stock Holding History

AssetMark Inc’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4K Buy
+177
New +$1.13K ﹤0.01% 3075

Other funds holding XERS

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AssetMark Inc's XERS Position: Q2 2026 in Review

AssetMark Inc opened a new position in Xeris Biopharma Holdings (XERS) in Q2 2026: 177 shares worth $1.4K. The stake represents ﹤0.01% of the portfolio and ranks #3075 among its holdings.

64 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • AssetMark Inc held 177 shares of Xeris Biopharma Holdings worth $1.4K as of Q2 2026.
  • Xeris Biopharma Holdings was a new AssetMark Inc position in Q2 2026.
  • Xeris Biopharma Holdings made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3075 holding.
  • 64 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.